Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

BACKGROUND: For many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin. This study compared gemcitabine and docetaxel versus doxorubicin as first-line treatment for advanced or metastatic soft-tissue sarcoma. METHODS: The GeDDiS trial was a rando...

Descripción completa

Detalles Bibliográficos
Autores principales: Seddon, Beatrice, Strauss, Sandra J, Whelan, Jeremy, Leahy, Michael, Woll, Penella J, Cowie, Fiona, Rothermundt, Christian, Wood, Zoe, Benson, Charlotte, Ali, Nasim, Marples, Maria, Veal, Gareth J, Jamieson, David, Küver, Katja, Tirabosco, Roberto, Forsyth, Sharon, Nash, Stephen, Dehbi, Hakim-Moulay, Beare, Sandy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622179/
https://www.ncbi.nlm.nih.gov/pubmed/28882536
http://dx.doi.org/10.1016/S1470-2045(17)30622-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622179/
https://www.ncbi.nlm.nih.gov/pubmed/28882536
http://dx.doi.org/10.1016/S1470-2045(17)30622-8

Ejemplares similares